Unlock stock picks and a broker-level newsfeed that powers Wall Street.

GE Aerospace’s Q1 results come ahead of estimates, annual guide reiterated

In This Article:

Investing.com -- GE Aerospace (NYSE:GE) reported first-quarter earnings and revenue that trumped analyst expectations.

The aerospace company posted Q1 earnings per share (EPS) of $1.49, well ahead of the consensus projection of $1.25. Revenue for the period came in at $9.94 billion, also topping the $9.14 billion estimated by analysts.

Shares in GE Aerospace rose less than 1% in premarket trading Tuesday.

In segment performance, commercial engines and services generated $6.98 billion in revenue, slightly above the $6.96 billion estimate.

Defense and propulsion technologies came in below expectations at $2.32 billion, compared to forecasts of $2.42 billion.

Adjusted free cash flow for the quarter was $1.44 billion, down 14% year-over-year and just under the $1.46 billion estimate.

“GE Aerospace had a strong start to 2025 with orders and revenue up double digits, driven by commercial services, and adjusted EPS up 60%. We continue to drive improvements through FLIGHT DECK, tackling supply chain constraints head on to accelerate deliveries throughout 2025," said GE Aerospace Chairman and CEO H. Lawrence Culp, Jr.

The company reaffirmed its full-year guidance, maintaining its adjusted EPS forecast of $5.10 to $5.45, compared with the analyst expectations of $5.42.

It also reiterated its outlook for adjusted free cash flow of $6.3 billion to $6.8 billion and adjusted operating profit of $7.8 billion to $8.2 billion.

"The macroeconomic dynamics we are operating in today require us to take a number of strategic actions, such as controlling costs, and leveraging available trade programs. Based on what we know today, these actions, along with our solid first quarter and commercial services backlog of over $140 billion, enable us to maintain our full-year guidance," Culp added.

Related articles

GE Aerospace’s Q1 results come ahead of estimates, annual guide reiterated

Cantor initiates coverage of U.S. large-cap pharma stocks: Gilead, AbbVie at Buy

Barclays downgrades Texas Instruments on China risk, demand concerns